Sirolimus Does Not Absolutely Abolish the Occurrence/Recurrence of Urothelial Carcinoma in Renal Transplant Recipients
Journal
Transplantation Proceedings
Journal Volume
40
Journal Issue
7
Pages
2395-2396
Date Issued
2008
Author(s)
Abstract
Objective: Sirolimus (SRL), an immunosuppressant shown to possess anti-proliferative properties, was hypothesized to mitigate the occurrence of posttransplantation malignancy. We examined its effect on posttransplantation urothelial carcinoma (UC). Methods: This retrospective case analysis included renal allograft recipients with UC treated with SRL in a single institute. Results: Among 90 renal recipients treated with SRL, 6 had previous/new-onset UC in the native kidney/ureter or bladder: at a mean period of 28 months (range, 7-49) of administering SRL for these recipients, UC occurred/recurred in 4 of the 6 patients. Individual cases are presented in detail. Conclusion: SRL does not absolutely abolish the occurrence/recurrence of UC among renal transplant recipients. Its potency as an anti-cancerous immunosuppressant for transplant recipients with UC deserves to be further defined in larger studies, probably by controlling SRL blood levels at lower or much higher ranges than used herein. ? 2008 Elsevier Inc. All rights reserved.
SDGs
Other Subjects
antineoplastic agent; basiliximab; cyclosporin; methylprednisolone; mycophenolic acid 2 morpholinoethyl ester; prednisolone; rapamycin; steroid; adult; anamnesis; article; cancer chemotherapy; cancer growth; cancer recurrence; controlled study; drug dose increase; drug dose reduction; female; human; immunosuppressive treatment; infection; kidney allograft; kidney graft rejection; kidney transplantation; major clinical study; male; nephroureterectomy; priority journal; transurethral resection; urogenital tract cancer; Adult; Antibiotics, Antineoplastic; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Sirolimus; Transplantation, Homologous; Treatment Failure; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms
Type
journal article